MTH1 expression is required for effective transformation by oncogenic HRAS

Oncotarget

Volumn 6, Issue 13, 2015, Pages 11519-11529

  Giribaldi, Maria G ^a,b   Munoz, Anisleidys ^a   Halvorsen, Katherine ^a,c   Patel, Asmita ^a,d   Rai, Priyamvada ^a,e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OPKA CURNA   (United States)

^d Beckman Coulter Inc   (United States)

^e UNIVERSITY OF MIAMI   (United States)

Author keywords

EMT; Glycolysis; MTH1; Oncogenic RAS; Transformation

Indexed keywords

GUANOSINE TRIPHOSPHATASE; PROTEIN MTH1; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 8-OXODGTPASE; DNA LIGASE; HRAS PROTEIN, HUMAN; PHOSPHATASE; PROTEIN P21;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CARCINOGENICITY; CELL POPULATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRAIT; GENETIC TRANSDUCTION; HRAS GENE; MALIGNANT TRANSFORMATION; ONCOGENE; PROTEIN EXPRESSION; TUMOR CELL; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; GLYCOLYSIS; HUMAN; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; OXIDATIVE STRESS; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA REPAIR ENZYMES; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; LUNG NEOPLASMS; OXIDATIVE STRESS; PHOSPHORIC MONOESTER HYDROLASES; PROTO-ONCOGENE PROTEINS P21(RAS); REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84929649409     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3447     Document Type: Article

References (36)

1. Downward J. Targeting RAS signalling pathways in cancer therapy. Nature reviews Cancer. 2003; 3:11-22.
2. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy:oncogene and non-oncogene addiction. Cell. 2009; 136:823-837.
3. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL, Lee SW. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011; 475:231-234.
4. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov. 2013; 12:829-846.
5. Patel A, Burton DG, Halvorsen K, Balkan W, Reiner T, Perez-Stable C, Cohen A, Munoz A, Giribaldi MG, Singh S, Robbins DJ, Nguyen DM, Rai P. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways. Oncogene. 2014; doi:10.1038/onc.2014.195.
6. Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Strom CE, Svensson LM, Schultz N, Lundback T, Einarsdottir BO, Saleh A, Gokturk C, Baranczewski P, Svensson R, Berntsson RP, Gustafsson R, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014; 508:215-221.
7. Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Gokturk C, Sanjiv K, Stromberg K, Pham T, Berglund UW, Colinge J, Bennett KL, Loizou JI, Helleday T, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014; 508:222-227.
8. Nakabeppu Y. Molecular genetics and structural biology of human MutT homolog, MTH1. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis. 2001; 477:59-70.
9. Rai P, Young JJ, Burton DG, Giribaldi MG, Onder TT, Weinberg RA. Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence. Oncogene. 2011; 30:1489-1496.
10. Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, Arnold RS, Lambeth JD. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A. 2002; 99:715-720.
11. Mitsushita J, Lambeth JD, Kamata T. The superoxidegenerating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res. 2004; 64:3580-3585.
12. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010; 107:8788-8793.
13. Sun B, Gao Y, Deng L, Li G, Cheng F, Wang X. The level of oncogene H-Ras correlates with tumorigenicity and malignancy. Cell Cycle. 2008; 7:934-939.
14. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002; 2:243-247.
15. Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 1991; 51:1744-1748.
16. Rai P, Onder TT, Young JJ, McFaline JL, Pang B, Dedon PC, Weinberg RA. Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence. Proc Natl Acad Sci U S A. 2009; 106:169-174.
17. Yang J, Weinberg RA. Epithelial-mesenchymal transition:at the crossroads of development and tumor metastasis. Developmental cell. 2008; 14:818-829.
18. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008; 68:3645-3654.
19. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119:1420-1428.
20. Lamouille S, Derynck R. Cell size and invasion in TGFbeta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol. 2007; 178:437-451.
21. Yates B, Zetterberg C, Rajeev V, Reiss M, Rittling SR. Promoter-independent regulation of vimentin expression in mammary epithelial cells by val(12)ras and TGFbeta. Exp Cell Res. 2007; 313:3718-3728.
22. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grunert S. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis:dissection of Ras signaling pathways. J Cell Biol. 2002; 156:299-313.
23. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009; 15:489-500.
24. Racker E, Resnick RJ, Feldman R. Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. Proc Natl Acad Sci U S A. 1985; 82:3535-3538.
25. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006; 25:4633-4646.
26. Mathupala SP, Ko YH, Pedersen PL. Hexokinase, II:cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006; 25:4777-4786.
27. Rai P. Human Mut T Homolog 1 (MTH1): A roadblock for the tumor-suppressive effects of oncogenic RAS-induced, ROS. Small GTPases. 2012; 3:13-12.
28. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Angela Nieto M, Werb Z, Bissell MJ. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005; 436:123-127.
29. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature reviews Cancer. 2009; 9:265-273.
30. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704-715.
31. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxiainducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res. 2005; 65:999-1006.
32. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001; 93:1062-1074.
33. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, Weinberg RA, Novina CD. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 2003; 9:493-501.
34. Patel A, Munoz A, Halvorsen K, Rai P. Creation and validation of a ligation-independent cloning (LIC) retroviral vector for stable gene transduction in mammalian cells. BMC biotechnology. 2012; 12:3.
35. Fei DL, Li H, Kozul CD, Black KE, Singh S, Gosse JA, DiRenzo J, Martin KA, Wang B, Hamilton JW, Karagas MR, Robbins DJ. Activation of Hedgehog signaling by the environmental toxicant arsenic may contribute to the etiology of arsenic-induced tumors. Cancer Res. 2010; 70:1981-1988.
36. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nature protocols. 2008; 3:1101-1108.